Studies on influenza haemagglutinin fusion peptide mutants generated by reverse genetics

AUTOR(ES)

Cross, Karen J.

FONTE

Oxford University Press

RESUMO

Influenza haemagglutinin (HA) is responsible for fusing viral and endosomal membranes during virus entry. In this process, conformational changes in the HA relocate the HA2 N-terminal ‘fusion peptide’ to interact with the target membrane. The highly conserved HA fusion peptide shares composition and sequence features with functionally analogous regions of other viral fusion proteins, including the presence and distribution of glycines and large side-chain hydrophobic residues. HAs with mutations in the fusion peptide were expressed using vaccinia virus recombinants to examine the requirement for fusion of specific hydrophobic residues and the significance of glycine spacing. Mutant HAs were also incorporated into infectious influenza viruses for analysis of their effects on infectivity and replication. In most cases alanine, but not glycine substitutions for the large hydrophobic residues, yielded fusion-competent HAs and infectious viruses, suggesting that the conserved spacing of glycines may be structurally significant. When viruses containing alanine substitutions for large hydrophobic residues were passaged, pseudoreversion to valine was observed, indicating a preference for large hydrophobic residues at specific positions. Viruses were also obtained with serine, leucine or phenylalanine as the N-terminal residue, but these replicated to significantly lower levels than wild-type virus with glycine at this position.

Documentos Relacionados

• Studies of the membrane fusion activities of fusion peptide mutants of influenza virus hemagglutinin.
• The structure of a membrane fusion mutant of the influenza virus haemagglutinin.
• Electron microscopy of antibody complexes of influenza virus haemagglutinin in the fusion pH conformation.
• Specific structural alteration of the influenza haemagglutinin by amantadine.
• The receptor-binding and membrane-fusion properties of influenza virus variants selected using anti-haemagglutinin monoclonal antibodies.